Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07415031 · ClinicalTrials.gov registry record · Phase 2
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
A Phase 2 study, sponsored by Mirati Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
NCT07415031: Recruiting Phase 2 study, sponsored by Mirati Therapeutics.
NCT07415031 is a Phase 2 study that is actively recruiting participants, run by Mirati Therapeutics. The registered enrollment target is 170 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07415031, a Phase 2 study, is actively recruiting participants, sponsored by Mirati Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
Study Summary
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.
Interventions
- DRUG Pembrolizumab
- DRUG Docetaxel
- DRUG Pemetrexed
- DRUG Cetuximab
- DRUG Adagrasib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2026-05-06 |
| Est. Completion | 2028-02-16 |
| Phase | Phase 2 |
What NCT07415031 shows while recruiting
NCT07415031 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% higher).
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT07415031 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07415031 about?
NCT07415031 is a clinical study titled "A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies". This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorect...
What is the current status of trial NCT07415031?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2026-05-06. Estimated completion is 2028-02-16.
What interventions are being tested in trial NCT07415031?
The interventions under investigation include: Pembrolizumab (DRUG), Docetaxel (DRUG), Pemetrexed (DRUG), Cetuximab (DRUG), Adagrasib (DRUG).
Who is sponsoring clinical trial NCT07415031?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07415031's enrollment target sits among peer trials
170 399th of 2000 higher than 1,598 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI